Real‑World Application of Autologous Hematopoietic Stem Cell Transplantation in 507 Patients With Multiple Sclerosis
Relapse free survival (RFS) at 5 years for RRMS and SPMS was 80.1% and 98.1%, respectively, while progression free survival (PFS) at 4 years for RRMS and SPMS was 95% versus 66%, respectively. For patients with RRMS, the EDSS signifcantly improved (p<0.0001) at each follow-up from a pre-HSCT mean of 3.87 to 2.51, 2.50, 2.41, 2.33, and 2.19 at 1, 2, 3, 4, and 5 years, respectively. For SPMS, the EDSS improved signifcantly only at 1 year but not thereafter. For SPMS, the mean baseline EDSS of 5.09 changed postHSCT to 4.85 (p=0.04), 4.88 (p=0.2), 4.92 (p=.27), 4.72 (p=0.07), and 4.2 (p=0.21) at 1, 2, 3, 4, 5 years, respectively...